Earnings Feed
Start Free
Seres Therapeutics, Inc.·4

Jul 10, 4:15 PM ET

DesRosier Thomas 4

Research Summary

AI-generated summary

Updated

Seres (MCRB) EVP Thomas DesRosier Receives 7,500-Share Award

What Happened Thomas DesRosier, EVP and Chief Legal Officer of Seres Therapeutics (MCRB), was granted a derivative equity award on July 8, 2026 for 7,500 shares at $0.00 per share (transaction code A). The filing identifies the award as an option; no cash was paid at grant. This is a compensation grant, not an open-market purchase or sale.

Key Details

  • Transaction date and type: 2026-07-08 — Grant of a derivative award (code A).
  • Quantity and price: 7,500 shares, $0.00 per share (grant value recorded as $0 in the filing).
  • Vesting: Footnote states the option vests 25% on March 2, 2027, with the remainder vesting in 12 equal quarterly installments thereafter.
  • Shares owned after transaction: Not specified in the filing.
  • Timeliness: Reported on Form 4 filed 2026-07-10 for the 2026-07-08 grant (appears timely).
  • Role: DesRosier is EVP and Chief Legal Officer (listed in remarks).

Context This was an equity compensation grant (an option) subject to future vesting based on continued service; it does not reflect an immediate market purchase or sale. Such grants are routine for executive compensation and should be interpreted as part of pay structure rather than a direct trading signal.